Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
anticompetitive, array, automated, ballot, Boston, broader, CDPA, coaching, contributor, CPRA, cycle, deadline, declaratory, Del, Delta, derecognition, devalue, disaggregated, dispute, disturbed, drawdown, DTx, dual, Durham, Dyno, Edgewise, EMBARK, Entrada, EudraCT, EURO, exacerbated, extrapolate, gap, GenEdit, Genevant, geolocation, HHS, ID, inaccessible, inconclusive, inconsistent, indemnify, inflow, input, intrusion, IPR, Journal, justification, largest, Mayo, MOMENTUM, moratorium, NC, NS, Omicron, outflow, PepGen, Pluma, post, provisionally, PYC, ran, ransomware, ratio, SAC, satisfactorily, span, Squibb, ST, Stephen, susceptible, topline, treble, unpatentable, Virginia, virtual, West
Removed:
advice, arithmetic, back, Bamboo, capability, cloud, comparable, computing, connected, consolidation, corroborated, credited, deducting, delisted, DMD, enactment, exceeded, exclusively, exhaust, exhausted, explore, fragment, hosting, hypothetical, invoice, judge, lifted, malfeasance, measuring, median, memorandum, merged, merger, module, notified, par, passing, pursued, quantitative, Reissue, repealed, Shire, sliding, stating, successive, supplied, Switzerland, taxing, trace, UNAUDITED, unconstitutional, vulnerable
Filing tables
Filing exhibits
Associated SRPT transcripts
SRPT similar filings
Filing view
External links
EXHIBIT 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the registration statements (No. 333-234698) on Form S-3ASR and (Nos. 333-101826, 333-172823, 333-175031, 333-192287, 333-199037, 333-209710, 333-213022, 333-34047, 333-49994, 333-49996, 333-221271, 333-228719, 333-233715 and 333-240996) on Form S-8 of our report dated March 1, 2022, with respect to the consolidated financial statements of Sarepta Therapeutics, Inc. and the effectiveness of internal control over financial reporting.
/s/ KPMG LLP
Boston, Massachusetts
March 1, 2022